RegeneRx Biopharmaceuticals Inc (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced on Thursday that a new patent from the Canadian Patent Office has been issued to the Henry Ford Health System (HFHS) intended for treating patients with peripheral neuropathy using Thymosin beta 4 (TBETA4).

TBETA4 is the active pharmaceutical ingredient in the company's proprietary drug candidate, RGN-352, a first-in-class injectable formulation aimed at systemic administration. Its use for the treatment of peripheral neuropathy or diabetic-induced vascular dysfunction has earlier been patented in several other countries including in the United States, EU, Asia and Israel.

The company in-licensed the intellectual property relating to the use of TBETA4 from the HFHS in Detroit, Michigan, based on work performed by Dr Michael Chopp and his colleagues. The patent is to expire in December 2032.